Alpha 2.0
Login Register
» Authors » Kohei Shiozaki

Kohei Shiozaki

Explore the profile of Kohei Shiozaki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 59
Followers 0
Related Specialties
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Masaya Akai
Tamotsu Ishizuka
Yoshiki Demura
Koki Nakashima
Toshihiko Tada
Mio Tabata
Masahiro Oi
Ken Nakagawa
Shiro Mizuno
Masaharu Iguchi
Published In
Intern Med
Respir Res
Chest
Medicine (Baltimore)
Affiliations
Soon will be listed here.
Recent Articles
1.
Utility of Endoscopic Ultrasound with Bronchoscope-guided Fine-needle Aspiration for Detecting Driver Oncogenes in Non-small-cell Lung Cancer during Emergency Situations: Case Series
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med . 2020 Nov; 60(7):1061-1065. PMID: 33132332
Since it is difficult to obtain tumor tissue via airway observation for lung cancer patients with a poor respiratory condition, endoscopic ultrasound with bronchoscope-guided fine-needle-aspiration (EUS-B-FNA), a transesophageal procedure, is...
2.
The Association between Malignant Pleural Mesothelioma and Thoracic Radiation Therapy for Hodgkin's Lymphoma: The First Case Report in Japan
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med . 2020 Oct; 60(5):771-775. PMID: 33055477
Malignant pleural mesothelioma (MPM) is mostly observed in patients with a history of asbestos exposure. Although other causes are rare, there are several reports of MPM induced by therapeutic radiation,...
3.
Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med . 2020 Jul; 59(23):3055-3059. PMID: 32727989
A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but...
4.
Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med . 2020 Mar; 59(11):1433-1435. PMID: 32161221
We herein report a 66-year-old woman with advanced lung adenocarcinoma [programmed cell death and its ligand 1 (PD-L1) tumor proportion score 60%] lacking driver oncogenes in whom meningeal carcinomatosis, along...
5.
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
Anzai M, Morikawa M, Okuno T, Umeda Y, Demura Y, Sonoda T, et al.
Medicine (Baltimore) . 2018 Feb; 96(51):e9320. PMID: 29390506
Background: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC)....
6.
p53 Signaling Pathway Polymorphisms Associated With Emphysematous Changes in Patients With COPD
Mizuno S, Ishizaki T, Kadowaki M, Akai M, Shiozaki K, Iguchi M, et al.
Chest . 2017 Mar; 152(1):58-69. PMID: 28315337
Background: The p53 signaling pathway may be important for the pathogenesis of emphysematous changes in the lungs of smokers. Polymorphism of p53 at codon 72 is known to affect apoptotic...
7.
Sirt1 expression is associated with CD31 expression in blood cells from patients with chronic obstructive pulmonary disease
Kato R, Mizuno S, Kadowaki M, Shiozaki K, Akai M, Nakagawa K, et al.
Respir Res . 2016 Oct; 17(1):139. PMID: 27784320
Background: Cigarette smoke induced oxidative stress has been shown to reduce silent information regulator 1 (Sirt1) levels in lung tissue from smokers and patients with COPD patients. Sirt1 is known...